Related Experiment Video
Updated: May 2, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Modeling Approaches to the Economic Evaluation of Microelimination Strategies for Hepatitis C Virus in High-Risk
Ying Chen1, Yun Bao2, Yueting Chen1
1Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Objectives:
Mathematical models inform hepatitis C virus (HCV) microelimination strategies in high-risk groups, but their reliability depends on underlying methodological choices. We systematically appraised the modeling methods used in economic evaluations of HCV microelimination published between 2015 and 2026.
Methods:
Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (International Prospective Register of Systematic Reviews: CRD420251185978), we searched PubMed/MEDLINE, Embase, and Web of Science for original studies using mathematical models to assess the cost-effectiveness of HCV interventions in high-risk populations. Using a structured extraction tool aligned with modeling best practices, we evaluated model conceptualization, structure, uncertainty handling, and validation. Reporting quality was assessed using the Consolidated Health Economic Evaluation Reporting Standards 2022 checklist.
Results:
Fifty-five studies met the inclusion criteria. Most relied on aggregate-level frameworks, comprising dynamic compartmental models (n = 25) and static Markov/decision-tree structures (n = 18), whereas 12 used individual-based models. People who inject drugs were the primary cohort in 30 evaluations. A pervasive limitation across the literature was the omission of endogenous behavioral feedback, with only 2 models allowing risk behaviors or service uptake to dynamically respond to intervention outcomes. Approximately half of the models (n = 28) synthesized parameters without a formal calibration process. Although parameter uncertainty was universally explored, external validation against real-world data was uncommon (n = 12) and, under our operational definition of distributional equity characterization, no study reported this assessment.
Conclusion:
Current economic models for HCV microelimination are technically sophisticated but frequently rely on structural simplifications-particularly the lack of dynamic behavioral feedback and network-based transmission-that may limit their real-world policy utility. Future efforts should prioritize data-driven network structures, rigorous external validation, and equity-informative frameworks to better support global elimination targets.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Hepatic Drug Excretion: Influencing Factors

